Key result
Gene-targeting experiments have elucidated the physiological functions of the type 1 (AT1) class of angiotensin receptors in the renin-angiotensin system.
This review highlights how gene-targeting technology has elucidated the physiological functions of the AT1 receptor in the renin-angiotensin system.
Consolidates evidence for AT1 blockade in cardiorenal disease; leaves open therapeutic potential of other RAS components.
The renin-angiotensin system (RAS) modulates a diverse set of physiological processes including development, blood pressure, renal function and inflammation. The principal effector molecule of this system, angiotensin II, mediates most of these actions. The classically recognized functions of the RAS are triggered via the type 1 (AT(1)) class of angiotensin receptors. Pharmacological blockade of the AT(1) receptor lowers blood pressure and slows the progression of cardiovascular and renal diseases. Gene-targeting technology provides an experimental approach for precisely dissecting the physiological functions of the RAS. Here, we review how gene-targeting experiments have elucidated AT(1) receptor functions.
No takes yet. Share an insight, caveat, or question.
Crowley et al. (2004) reported a review. Gene-targeting experiments was evaluated. Gene-targeting experiments have elucidated the physiological functions of the type 1 (AT1) class of angiotensin receptors in the renin-angiotensin system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: